期刊
NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 37, 期 5, 页码 810-816出版社
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa249
关键词
cytomegalovirus; kidney transplantation; mTOR; prophylaxis; valganciclovir
CMV-related complications after kidney transplantation present a significant challenge. Tailoring preventive strategies based on individual patient risk levels can improve outcomes. CMV-specific T-cell assays can help predict CMV risk pre-transplantation. Immunosuppressive regimens including mammalian target of rapamycin inhibitors can reduce CMV risk. New antiviral agents and adoptive T-cell therapy hold promise for future treatment options.
Cytomegalovirus (CMV)-related complications after kidney transplantation remain a substantial challenge. Rather than applying one preventive strategy to all at-risk patients, we can now adapt our strategy at the individual patient level. Antiviral prophylaxis or a strict pre-emptive strategy may be optimal for patients at the highest risk for CMV, while patients at lower risk may benefit particularly from pre-emptive monitoring and the administration of therapy only if needed. CMV-specific T-cell assays may be useful for further refining the pre-transplant determination of CMV risk, and for guiding decisions about antiviral therapy need or duration. An immunosuppressive regimen including a mammalian target of rapamycin inhibitor reduces CMV risk and may thus be an attractive option in some patients. New antiviral agents may further expand our therapeutic arsenal in the near future, and the prospects of CMV vaccination and adoptive T-cell therapy appear to be on the horizon.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据